(NASDAQ: ADPT) Adaptive Biotechnologies's forecast annual revenue growth rate of 15.88% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.26%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Adaptive Biotechnologies's revenue in 2024 is $170,276,000.On average, 5 Wall Street analysts forecast ADPT's revenue for 2024 to be $25,708,464,222, with the lowest ADPT revenue forecast at $25,057,435,202, and the highest ADPT revenue forecast at $26,856,579,362. On average, 5 Wall Street analysts forecast ADPT's revenue for 2025 to be $33,167,512,782, with the lowest ADPT revenue forecast at $30,106,646,233, and the highest ADPT revenue forecast at $37,201,658,284.
In 2026, ADPT is forecast to generate $40,661,528,579 in revenue, with the lowest revenue forecast at $39,334,514,668 and the highest revenue forecast at $42,281,338,692.